



For immediate release April 26, 2013

Communiqué from Annual General Meeting for Genovis AB (publ) April 25, 2013

The following decisions were adopted at the Annual General Meeting:

The balance sheet and income statement were ratified.

The Board of Directors and the CEO were discharged from liability.

The Board shall consist of seven ordinary members with no alternates until the next Annual General Meeting.

Ebba Åsly Fåhraeus, Thomas Laurell, Kenth Petersson, Carina Schmidt, Jacob Engellau, Peter Ragnarsson and Erik Walldén were re-elected as Board members.

Ebba Åsly Fåhraeus was re-elected as Chairman of the Board.

A Nominating Committee shall be formed and consist of representatives of the four largest shareholders at September 30, 2013, who are not members of the Board.

Guidelines for remuneration for the CEO and other leading employees were ratified in accordance with the Board's proposal.

For additional information please contact:
Sarah Fredriksson, CEO of Genovis AB
Tel: +46 (0)46-10 12 35
e-mail: sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis' business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00